SCHEMBL29908846

SCHEMBL29908846

O=P(O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 7/20 0.75
P2RX3 P56373 6/20 0.75
P2RX2 Q9UBL9 6/20 0.75
P2RY2 P41231 3/20 0.75
P2RX4 Q99571 2/20 0.75
P2RX1 P51575 2/20 0.75
SRC P12931 2/20 0.75
SMN1; SMN2 Q16637 2/20 0.75
ALDH1A1 P00352 1/20 0.75
RNASEL Q05823 1/20 0.72
TRPM2 O94759 2/20 0.70
MACROD2 A1Z1Q3 1/20 0.70
SIRT6 Q8N6T7 1/20 0.70
MACROD1 Q9BQ69 1/20 0.70
GPR17 Q13304 1/20 0.70
DNPH1 O43598 1/20 0.66
PRKAB2 O43741 1/20 0.66
LDHA P00338 1/20 0.66
ADRB2 P07550 1/20 0.66
FBP1 P09467 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1331755 1.00 P2RY1 (0.75) P2RY1P2RX3P2RX2P2RY2P2RX4
SCHEMBL163281 1.00 P2RY1 (0.75) P2RY1P2RX3P2RX2P2RY2P2RX4
SCHEMBL163282 1.00 P2RY1 (0.75) P2RY1P2RX3P2RX2P2RY2P2RX4
SCHEMBL1331745 1.00 P2RY1 (0.75) P2RY1P2RX3P2RX2P2RY2P2RX4
SCHEMBL5365040 1.00 P2RY1 (0.75) P2RY1P2RX3P2RX2P2RY2P2RX4
SCHEMBL27837591 0.99 P2RY1 (0.74) P2RY1P2RX3P2RX2P2RY2P2RX4
SCHEMBL28009685 0.99 P2RY1 (0.74) P2RY1P2RX3P2RX2P2RY2P2RX4
Pyrophosphoric Acid SCHEMBL27579246 0.99 P2RY1 (0.74) P2RY1P2RX3P2RX2P2RY2P2RX4
SCHEMBL29134096 0.99 P2RY1 (0.74) P2RY1P2RX3P2RX2P2RY2P2RX4
SCHEMBL23711717 0.99 P2RX3 (0.74) P2RY1P2RX3P2RX2P2RY2P2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120989190-A Preparation method for preparing inosine 5' -triphosphate through enzyme catalysis 上海日冠生物科技有限公司 2025-11-21 CN disclosed
CN-120989190-A Preparation method for preparing inosine 5' -triphosphate through enzyme catalysis 上海日冠生物科技有限公司 2025-11-21 CN disclosed
CN-120944989-A Preparation method of inosine 5 '-triphosphate and inosine 5' -triphosphate 上海日冠生物科技有限公司 2025-11-14 CN disclosed
CN-120944989-A Preparation method of inosine 5 '-triphosphate and inosine 5' -triphosphate 上海日冠生物科技有限公司 2025-11-14 CN disclosed
US-20250213580-A1 Improved Thiopurine Formulation and Treatment Methods DOUGLAS PHARMACEUTICALS LTD (NZ) 2025-07-03 US disclosed
CN-119799819-A Preparation method for preparing inosine-5' -diphosphate by enzyme catalysis 上海日冠生物科技有限公司 2025-04-11 CN disclosed
EP-4499105-A1 IMPROVED THIOPURINE FORMULATION AND TREATMENT METHODS Douglas Pharmaceuticals Limited (NZ) 2025-02-05 EP disclosed
CN-118946361-A Improved thiopurine formulations and methods of treatment 道格拉斯制药有限公司 2024-11-12 CN disclosed
EP-4437125-A1 RNA AND DNA ANALYSIS USING ENGINEERED SURFACES Alida Biosciences, Inc. (US) 2024-10-02 EP disclosed
CN-118660973-A RNA and DNA analysis Using engineered surfaces 阿丽达生物科学公司 2024-09-17 CN disclosed
CN-113474644-B Electrode and electrochemical measurement system 日东电工株式会社 2024-04-12 CN disclosed
CN-117795096-A Methods, compositions and kits for preparing sequencing libraries 吉复生物科技有限公司 2024-03-29 CN disclosed
CN-117042767-A Methods of treating cancer using STING agonists 丹娜法伯癌症研究院 2023-11-10 CN disclosed
WO-2023182895-A1 IMPROVED THIOPURINE FORMULATION AND TREATMENT METHODS DOUGLAS PHARMACEUTICALS LTD (NZ) 2023-09-28 WO disclosed
CN-111511754-B 2'3' cyclic dinucleotides with phosphonate bonds of activated STING adaptor protein 捷克共和国有机化学与生物化学研究所 2023-09-12 CN disclosed
WO-2023097295-A1 RNA AND DNA ANALYSIS USING ENGINEERED SURFACES ALIDA BIOSCIENCES, INC. (US) 2023-06-01 WO disclosed
EP-4093882-A1 VIRUS DETECTION Sense Biodetection Limited (GB) 2022-11-30 EP disclosed
CN-115003828-A Virus detection 圣斯生物检测有限公司 2022-09-02 CN disclosed